Drug sales in France, Europe's second largest market, are expected to decline more than 3% this year as the government continues to reduce health care spending through price cuts and greater use of generics, according to the pharmaceutical intelligence firm IMS Health. By contrast, other mature markets like the United States, Germany and Japan should register slight increases, and growth rates in Brazil and China may exceed 10%. This is the second consecutive year of declines in France.

Related Summaries